Pilot study of nivolumab in pediatric patients with hypermutant cancers.

10011Background: Responses to immune checkpoint inhibitors (ICI) in unselected pediatric solid tumors have been disappointing. We hypothesized that pediatric cancers with an increased tumor mutatio...